When a payer denies a specialty-drug prescription because the patient has not completed step therapy, the prescriber can request an exception. But not all exceptions are equal. Payers recognize distinct grounds—contraindication, adverse event or intolerance, and inadequate response—and each demands a different type of clinical documentation. Submitting the wrong evidence type is the single most common reason step therapy exception requests fail.
This article maps each exception category to the documentation payers actually require, the recurring gaps that trigger denials, and the operational workflow access teams should follow. It is written for manufacturer hub teams, field reimbursement specialists, provider-office access coordinators, and specialty pharmacy staff who build or review step therapy exception packages.
The three recognized exception grounds
Across commercial payers, Medicare Advantage plans, and Medicaid managed care, step therapy exception criteria converge on three categories. State laws in at least 35 states codify these same grounds. The CMS proposed rule on interoperability and prior authorization for drugs (CMS-0062-P, published April 2026 in the Federal Register) explicitly references these exception categories and asks for comment on how technology can streamline them. The nationally recognized exception grounds are:
| Exception ground | What the payer must see | Burden of proof |
|---|---|---|
| Contraindication | The required step drug is medically contraindicated for this patient | Binary — if a true contraindication exists, the step requirement cannot be enforced |
| Adverse event or intolerance | The patient tried the step drug and experienced a clinically significant adverse event, or prior use of a pharmacologically similar drug caused an adverse event | Documented trial with specific adverse event description |
| Inadequate response | The patient tried the step drug at an adequate dose for an adequate duration and did not achieve a sufficient clinical response | Documented trial at therapeutic dose for adequate duration with measured outcome |
A fourth ground—patient stability on the requested drug—exists in many state laws and some payer policies. If the patient is currently stable on the non-preferred drug (often due to a change in insurance or formulary), many payers will grant an exception without requiring a new trial of the step-preferred agent.
Contraindication: the strongest but narrowest ground
Contraindication is the strongest exception ground because it is binary. If a true contraindication exists, the step requirement is medically inappropriate and the payer must grant the exception. But the bar is high: the documentation must establish a specific, recognized contraindication—not a vague concern about possible side effects.
What constitutes a contraindication
Payers generally accept these as contraindication evidence:
- FDA boxed warning or contraindication section of the prescribing information that applies to the patient's specific clinical situation (e.g., a patient with a history of Stevens-Johnson syndrome and a step drug whose label contraindicates use in patients with prior severe cutaneous adverse reactions)
- Documented allergy in the medical record, particularly IgE-mediated or anaphylactic reactions
- Severe drug-drug interaction that cannot be managed by dose adjustment or monitoring, documented with the interacting medication and a clinical reference (e.g., Micromedex or clinical pharmacology interaction rating of "major" or "contraindicated")
- Comorbidity that makes the drug inappropriate (e.g., severe renal impairment when the step drug is renally cleared and the label specifies CrCl thresholds)
What does NOT qualify as a contraindication
Payers routinely reject:
- "Patient prefers not to take" the step drug
- "Patient is concerned about side effects" without documented prior adverse event
- Interactions rated "use with caution" or "minor" without clinical evidence of harm
- General statements like "may cause adverse effects" without specifying the clinical basis
Documentation package for contraindication
A strong contraindication exception package should include:
- Physician attestation citing the specific contraindication and the clinical basis
- Relevant medical record documentation: allergy history, lab values (e.g., creatinine clearance), current medication list with interaction analysis
- Prescribing information reference: the specific section of the step drug's label that establishes the contraindication
- Clinical reference if the contraindication is based on a drug interaction (e.g., Lexicomp or Micromedex printout)
Adverse event or intolerance: the most commonly misfiled ground
The adverse event exception is the most common ground cited but the most commonly misdocumented. Payers distinguish between true adverse events (documented, clinically significant reactions) and general intolerance or non-specific complaints.
Key distinction: adverse event vs expected side effect
Some payers, including UnitedHealthcare's Medicare Advantage Part B step therapy program effective January 2026, explicitly state that adverse events must be "not an expected adverse event attributed to the active ingredient as described in the prescribing information." This means a common side effect listed in the label may not qualify as a standalone exception ground unless the severity or clinical impact exceeds what is expected.
What payers require for adverse event documentation
- Trial dates: when the patient started and stopped the step drug
- Dose: the dose at which the adverse event occurred
- Duration: how long the patient was on the drug before the event
- Specific adverse event: the exact reaction (not "had side effects" but "developed grade 3 hepatotoxicity with ALT 5× ULN on date X")
- Clinical action taken: dose reduction, discontinuation, hospitalization, emergency department visit
- Supporting documentation: lab values, imaging, specialist consultation notes, or chart notes from the treating period
Common documentation gaps
A 2026 analysis from ezAppeal found that the most frequent reason for adverse event-based exception denial is insufficient specificity. The gap is not whether the patient had a reaction but whether the documentation proves it:
| Gap | What the denial letter says | What should have been submitted |
|---|---|---|
| Vague description | "Insufficient documentation of adverse event" | Specific event name, grade/severity, and clinical impact |
| No dates | "Cannot verify timing of adverse event" | Start date, event date, discontinuation date |
| Expected side effect | "Adverse event is consistent with known drug profile" | Documentation of severity exceeding expected range or clinical consequence |
| No chart notes | "No clinical documentation provided" | Office visit notes from the period the event occurred |
The pharmacologically similar drug issue
Some payer policies allow an exception when the patient experienced an adverse event with a drug in the same pharmacologic class. For example, Blue Cross Blue Shield of Michigan's step therapy criteria (revised December 2025, effective January 2026) allow exception when "prior attempts to use the same or a pharmacologically similar drug were discontinued because it was ineffective, had a diminished effect, or caused an adverse event." Oregon's step therapy exception form (2025 revision) explicitly includes drugs with the same mechanism of action.
However, the documentation must establish the pharmacologic similarity and the adverse event with the same specificity as a direct trial failure.
Inadequate response: the most documentation-intensive ground
Inadequate response (also called treatment failure or lack of efficacy) is the most documentation-intensive exception category. Payers want proof that the patient had an adequate trial—meaning therapeutic dose for adequate duration—and that the clinical response was objectively measured and insufficient.
The adequate trial requirement
The definition of "adequate" varies by drug class and payer, but these are the general standards:
| Drug class | Typical adequate trial | What payers measure |
|---|---|---|
| Biologic DMARDs for rheumatoid arthritis | 3–6 months at target dose | DAS28, CDAI, RAPID-3, or joint count improvement |
| Oral oncolytics (CML) | 3 months at therapeutic dose | Molecular response (BCR-ABL), hematologic response |
| Biologics for inflammatory bowel disease | 8–14 weeks induction | Mayo score, SES, fecal calprotectin, CRP |
| GLP-1 receptor agonists for diabetes | 3–6 months at max tolerated dose | A1C reduction from baseline |
| Targeted therapies (oncology) | 2–3 cycles at label dose | RECIST criteria, biomarker response |
The critical documentation elements for inadequate response are:
- Start date and end date of the step drug trial
- Dose: must be at or near the FDA-recommended dose for the indication (subtherapeutic dosing will not satisfy the payer)
- Duration: must meet the minimum trial length in the payer's criteria or clinical guidelines
- Baseline measurement: the disease severity metric before starting the step drug
- Follow-up measurement: the same metric after the adequate trial period
- Clinical interpretation: a statement from the prescriber explaining why the response was inadequate
The specific-vs-general documentation difference
A real-world example from the ezAppeal 2026 analysis illustrates the gap:
Weak documentation: "Patient tried methotrexate without adequate response."
Strong documentation: "Patient completed a 12-week trial of methotrexate at 20 mg weekly with persistent disease activity as measured by DAS28-CRP of 5.2 at week 12 (baseline 5.8), documented on March 15, 2026."
The second version matches the payer's own clinical criteria language and gives the reviewer everything needed to approve the exception in a single pass.
State law overlay: where the rules diverge
At least 35 states have enacted step therapy reform laws that codify these exception grounds and impose timelines on payer responses. Key variations include:
| State | Exception grounds | Response timeline | Notable provisions |
|---|---|---|---|
| California | Contraindication, adverse event, expected ineffectiveness, stability on current drug | 72 hours non-urgent, 24 hours urgent | Step therapy must follow clinical practice guidelines |
| Colorado | Contraindication, adverse reaction, ineffectiveness, prior trial failure, stability | 2 business days (ePA), 3 business days (non-urgent) | Clinical criteria and exception process must be available online |
| New York | Contraindication, prior adverse event, expected ineffectiveness | 3 business days (non-urgent), 24 hours (urgent) | Applies to both pharmacy and medical benefit |
| Oregon | Contraindication, expected ineffectiveness, prior trial failure (same class or mechanism), stability, clinical exception | 72 hours or 2 business days (whichever is later), 1 business day (urgent) | Includes drugs with same mechanism of action |
| Wisconsin | Contraindication, adverse reaction, expected ineffectiveness, clinical harm | 3 business days (non-urgent), next business day (urgent) | Must consider known clinical characteristics of patient and drug |
For specialty-drug access teams, this means the exception strategy should always account for the governing state law, which may provide broader grounds or shorter timelines than the payer's own policy.
Operational workflow for step therapy exception submissions
For hub teams and access coordinators, the following workflow reduces exception denial rates:
Step 1: Identify the exception ground
Before starting documentation, determine which ground applies. Do not default to "treatment failure" when the real reason is contraindication—the documentation requirements are different and using the wrong ground weakens the submission.
Step 2: Pull the payer's specific criteria
Most payers publish their step therapy criteria online. Pull the actual policy document and mirror its language. If the policy says "moderate-to-severe disease as defined by a score of X or higher on [assessment tool]," include that score and that tool.
Step 3: Assemble documentation by exception type
Use the evidence checklist for the relevant ground:
Contraindication checklist:
- Physician attestation citing specific contraindication
- Relevant medical record documentation (allergy, lab, medication list)
- Prescribing information reference (specific section)
- Drug interaction analysis (if applicable)
Adverse event checklist:
- Trial dates (start, event, stop)
- Dose at time of event
- Specific adverse event with severity grade
- Clinical action taken
- Supporting chart notes and lab values
Inadequate response checklist:
- Trial dates with duration calculation
- Dose (confirm therapeutic range)
- Baseline measurement
- Follow-up measurement (same metric)
- Prescriber interpretation of inadequate response
Step 4: Date everything
Every trial, lab result, office visit, and adverse event must have a date. Payers cannot verify step therapy failure without a timeline.
Step 5: Submit through the correct channel
Determine whether the exception goes through the pharmacy benefit (typically the PBM portal) or the medical benefit (the health plan directly). Aetna, for example, requires separate exception request processes for pharmacy-benefit drugs (processed through CVS Caremark) and medical-benefit drugs (processed through Aetna directly). The commercial exception deadline is 180 days; Medicare Advantage is 60 days.
What the 2026 CMS proposed rule may change
The CMS proposed rule on interoperability and prior authorization for drugs (CMS-0062-P, April 2026) includes several provisions that may reshape step therapy exception workflows:
- Electronic step therapy: CMS seeks comment on how technology can facilitate step therapy determinations and whether payers should honor step therapy completion from other payers via the Payer-to-Payer API
- FHIR-based data exchange: The proposed rule would require impacted payers to support electronic prior authorization for drugs using FHIR-based standards, which could enable automated verification of prior trial history
- Transparency requirements: Payers would be required to make step therapy criteria available through standardized API endpoints
If finalized, these provisions could reduce the documentation burden for step therapy exceptions by allowing payers to access historical prescription claims data directly. Until then, the manual documentation workflow described above remains the standard.
What to monitor
- CMS-0062-P final rule timeline: If finalized, electronic step therapy verification could begin as early as 2027 for Medicare Advantage and Medicaid managed care
- State step therapy reform legislation: At least 35 states have enacted laws; additional states are considering bills in 2026 sessions
- Payer criteria updates: Step therapy criteria are typically updated annually or semi-annually; access teams should verify current criteria before each submission
- Biosimilar step therapy: As more biosimilars enter the market, payers are adding biosimilar step therapy requirements. A 2026 Tufts Medical Center analysis found that 75% of oncology step therapy policies now require biosimilars or generics before branded products
This article is for informational purposes only and does not constitute medical advice, legal advice, or reimbursement guidance for any specific patient or plan. Coverage policies vary by payer, plan, and state. Always verify current payer criteria before submitting a step therapy exception request.
Last updated: May 31, 2026.
Sources
- CMS. "2026 CMS Interoperability Standards and Prior Authorization for Drugs Proposed Rule (CMS-0062-P)." April 14, 2026. cms.gov
- Federal Register. "Medicare and Medicaid Programs: Interoperability Standards and Prior Authorization for Drugs." 91 FR 19891. April 14, 2026. federalregister.gov
- Triage Cancer. "Health Insurance State Laws: Step Therapy." 2026. triagecancer.org
- Step Therapy (National Psoriasis Foundation). "Step Therapy Legislation by State." 2026. steptherapy.com
- American Medical Association. "2024 Prior Authorization State Law Chart." 2024. ama-assn.org
- Blue Cross Blue Shield of Michigan. "Prior Authorization and Step Therapy Coverage Criteria." Revised December 2025, effective January 2026. bcbsm.com
- Neighborhood Health Plan of Rhode Island. "Step Therapy Exception Criteria." Revised January 2026. nhpri.org
- Oregon Division of Financial Regulation. "Supporting Information for Step Therapy Exception Request." 2025. csro.info
- AMCP. "Prior Authorization." 2026. amcp.org
- Tufts Medical Center CEVR. "Trends in Utilization Management for Oncology Therapies Amongst US Commercial Health Plans: 2017-2024." May 2026. cevr.tuftsmedicalcenter.org
- ezAppeal. "Prior Authorization Requirements for Specialty Medications — April 2026." ezappeal.com
- Muni Health. "Aetna Step Therapy Denial Appeal 2026." May 2026. muni.health
- UnitedHealthcare. "Medicare Part B Step Therapy Programs." Effective January 1, 2026. uhcprovider.com
